1-Jahres-Chart
5-Tage-Chart
| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 126,00 | 132,00 | 15.05. |
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Mi | Belite Bio, Inc: Belite Bio to Host Webcast on May 20, 2026, to Discuss First Quarter 2026 Financial Results | 4 | GlobeNewswire (USA) | ||
| 21.04. | Belite Bio begins rolling NDA submission for Stargardt treatment | 1 | Investing.com | ||
| 21.04. | Belite Bio startet schrittweises Zulassungsverfahren für Stargardt-Therapie | 1 | Investing.com Deutsch | ||
| 21.04. | Belite Bio, Inc: Belite Bio Initiates Rolling Submission of New Drug Application to the U.S. Food and Drug Administration for Tinlarebant for the Treatment of Stargardt Disease | 468 | GlobeNewswire (Europe) | Belite expects to complete the new drug application submission in the second quarter of 2026Rolling submission initiated under Breakthrough Therapy Designation SAN DIEGO, April 21, 2026 (GLOBE NEWSWIRE)... ► Artikel lesen | |
| 21.04. | BELITE BIO, INC - 6-K, Report of foreign issuer | - | SEC Filings | ||
| 13.04. | H.C. Wainwright bekräftigt "Buy"-Rating für Belite Bio mit Kursziel 200 $ | 1 | Investing.com Deutsch | ||
| 07.04. | Benchmark bestätigt Rating für Belite Bio aufgrund solider Liquidität und Studienfortschritt | 2 | Investing.com Deutsch | ||
| BELITE BIO Aktie jetzt für 0€ handeln | |||||
| 31.03. | Belite Bio reports FY results | 1 | Seeking Alpha | ||
| 31.03. | Belite Bio, Inc: Belite Bio Announces Availability of Annual Report on Form 20-F Through Company Website | 1 | GlobeNewswire (USA) | ||
| 31.03. | BELITE BIO, INC - 6-K, Report of foreign issuer | - | SEC Filings | ||
| 31.03. | BELITE BIO, INC - 20-F, Annual and transition report of foreign private issuers | - | SEC Filings | ||
| 09.03. | Belite Bio: Positive Phase-3-Studiendaten für Tinlarebant bei Morbus Stargardt | 1 | Investing.com Deutsch | ||
| 04.03. | Mizuho reiterates Belite Bio stock rating on NDA timeline update | 1 | Investing.com | ||
| 04.03. | H.C. Wainwright raises Belite Bio stock price target on NDA timeline | 2 | Investing.com | ||
| 03.03. | Cantor Fitzgerald raises Belite Bio stock price target on pricing outlook | 3 | Investing.com | ||
| 03.03. | Belite Bio targets Q2 2026 NDA submission and $200M-$250M commercialization spend for Stargardt therapy while cash reserves surge | 2 | Seeking Alpha | ||
| 02.03. | Belite Bio Non-GAAP EPS of -$0.19 beats by $0.38 | 2 | Seeking Alpha | ||
| 02.03. | Belite Bio, Inc: Belite Bio Reports Preliminary, Unaudited Fourth Quarter and Full Year 2025 Financial Results and Provides a Corporate Update | 408 | GlobeNewswire (Europe) | Following positive topline results from the pivotal, global Phase 3 DRAGON trial of tinlarebant in adolescents with Stargardt disease type 1 (STGD1), the Company is on track to submit a New Drug Application... ► Artikel lesen | |
| 27.02. | Exploring Belite Bio's Earnings Expectations | 1 | Benzinga.com | ||
| 30.01. | BELITE BIO, INC - S-8, Securities to be offered to employees in employee benefit plans | 1 | SEC Filings |
1 2 3 Weiter >>
52 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| BIONTECH | 76,40 | -2,98 % | BioNTech-Krise vs. Emyria-Durchbruch? Warum Daten jetzt die Forschung schlagen | ||
| PALATIN TECHNOLOGIES | 14,990 | +2,11 % | PALATIN TECHNOLOGIES INC - 10-Q, Quarterly Report | ||
| OCUGEN | 1,182 | -1,66 % | Ocugen schließt Platzierung von Wandelanleihen über 130 Millionen US-Dollar ab | ||
| SANGAMO THERAPEUTICS | 0,126 | 0,00 % | XFRA GBY: AUSSETZUNG/SUSPENSION | DAS/ DIE FOLGENDE(N) INSTRUMENT(E) IST/ SIND AB SOFORT AUSGESETZT:THE FOLLOWING INSTRUMENT(S) IS/ ARE SUSPENDED WITH IMMEDIATE EFFECT:INSTRUMENT NAME KUERZEL/SHORTCODE ISIN BIS/UNTILSANGAMO THERAP.INC.DL-... ► Artikel lesen | |
| VIKING THERAPEUTICS | 26,400 | +1,15 % | Viking Therapeutics, Inc.: Viking Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update | Conference call scheduled for 4:30 p.m. ET today
-- Phase 3 VANQUISH Trials for Subcutaneous VK2735 in Obesity Advance; VANQUISH-1 and VANQUISH-2 Trials Fully Enrolled... ► Artikel lesen | |
| INFLARX | 1,950 | -8,45 % | InflaRx schließt Kapitalerhöhung über 150 Millionen Dollar ab | Wie angekündigt hat InflaRx die Platzierung von 75 Millionen Stammaktien zu je 2,00 US-Dollar abgeschlossen. Der Bruttoerlös beläuft sich nach Angaben des Jenaer Biotechnologie-Unternehmens auf 150... ► Artikel lesen | |
| EDITAS MEDICINE | 2,250 | -0,44 % | Editas Medicine, Inc.: Editas Medicine Reports New Preclinical Data Demonstrating Progress of EDIT-401 as Potential Treatment for Hyperlipidemia at the American Society of Gene and Cell Therapy 2026 Annual Meeting | CAMBRIDGE, Mass., May 14, 2026 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a pioneering gene editing company developing transformative medicines for serious diseases, shared new preclinical... ► Artikel lesen | |
| ABIVAX | 100,00 | +0,86 % | EQS-News: ABIVAX: Abivax Announces Results of its May 11, 2026 Annual General Meeting | EQS-News: ABIVAX
/ Key word(s): AGM/EGM
Abivax Announces Results of its May 11, 2026 Annual General Meeting
11.05.2026 / 22:05 CET/CEST
The issuer is solely responsible... ► Artikel lesen | |
| SAREPTA THERAPEUTICS | 15,240 | +0,93 % | Biotech-Player: Zelltherapie als Comeback-Story im Milliardenmarkt. Neue Ideen nach Corona von BioNTech, Qiagen und Biotech AG | ||
| CARDIOL THERAPEUTICS | 1,152 | +1,05 % | Stocks in Play: Cardiol Therapeutics Inc. | ||
| GERON | 1,155 | +3,63 % | Geron Corporation: First Real-World Evidence Study of RYTELO (imetelstat) in Lower-risk Myelodysplastic Syndromes (LR-MDS) to be Presented at EHA 2026 | ||
| BASILEA | 60,20 | +0,33 % | Basilea Pharmaceutica International Ltd, Allschwil: Basilea-Aktionäre genehmigen an der Generalversammlung 2026 alle Anträge des Verwaltungsrats | Allschwil, 15. April 2026
Basilea Pharmaceutica AG, Allschwil (SIX: BSLN), ein biopharmazeutisches Unternehmen mit bereits vermarkteten Produkten und dem Ziel, Patienten zu helfen, die an schweren... ► Artikel lesen | |
| ARROWHEAD PHARMACEUTICALS | 65,68 | -0,45 % | Arrowhead Pharmaceuticals, Inc.: Arrowhead Pharmaceuticals to Participate in Upcoming May 2026 Events | Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that it is scheduled to participate in the following upcoming events:
BofA Securities 2026 Healthcare Conference May 12-14, 2026
Type:... ► Artikel lesen | |
| CELLECTAR BIOSCIENCES | 3,150 | +1,94 % | Cellectar Biosciences, Inc.: Cellectar Biosciences Reports First Quarter 2026 Financial Results and Provides Corporate Updates | Announced Positive 12-month Follow-on Data for Iopofosine I 131 in relapsed/refractory Waldenström Macroglobulinemia (r/r WM) Completed Financing of up to $140 Million to Support Initiation of Confirmatory... ► Artikel lesen | |
| TELIX PHARMACEUTICALS | 9,000 | -0,21 % | EDAP TMS S.A.: EDAP | Focal One and Telix Announce Collaboration Focused on Robotic HIFU and Theranostics in Prostate Cancer | , May 14, 2026 (GLOBE NEWSWIRE) -- AUSTIN, Texas - May 14, 2026 - EDAP TMS S.A. (Nasdaq: EDAP) today announced that it has entered into a letter of intent with Telix Pharmaceuticals Limited ("Telix")... ► Artikel lesen |
Das Unternehmen BELITE BIO INC ADR kann der Branche Biotechnologie zugeordnet werden. Der aktuelle Kurs liegt bei 122,00 Euro und damit -4,69 % im Minus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu BELITE BIO INC ADR finden Sie auf Wallstreet Online.